预约演示

A Christmas deal spree: See what J&J, Roche and more had in their stockings

2024-01-02

交易

引进/卖出并购抗体药物偶联物细胞疗法临床1期

Biopharma didn't slow down the dealmaking over Christmas. We recap what companies picked up and put in their stockings over the holiday break.

You think Santa can stop the biotech deal making train? Think again. A handful of companies couldn’t wait for the New Year—or next week’s JP Morgan Healthcare conference—to announce their latest wheeling and dealing. We recap the Christmas deal spree below.

>> Johnson & Johnson picked up licensing rights to LegoChem Biosciences’ Trop2 directed antibody drug conjugate (ADC) LCB84 for $100 milliJP Morgan Healthcare billion in potential milestones down the line, according to a December 26 press release.

J&JJohnson & Johnsonill gain exclusive, worldwide rLegoChem Biosciences cTrop2cialize the solid tumor and hematologicaLCB84cer med LCB84, which is currently in a phase 1/2 trial.

J&J heJanssene giant becomes the latest Big Pharma to team up with South Korea’s LegoChem,solid tumored a hematological cancerith ALCB84for up to five ADC options in December 2022.

The deal follows a frenzy in ADCs among Big Pharmas and an exciting array of dataLegoChemed in the field at the European Society fAmgendical Oncology mADCing in Madrid in October 2023.

>> Roche also couldn’t stay away from the ADC excitement, inking a deal with China’s MediLink—known as Suzhou Yilian Biopharmaceutical Co. in that country. According to a Jan. 2 release, Roche is putting down an unspecified upfront payment plus near-term milestones of $50 million and a potential $1 billion in other milestones down the line. The deal also includes royalties on future sales.

TheRoches pharma will snag exclusive rights to YL211, a mesenchymal epidermal transfoMediLinkctor (c-MET) ADC under development for solid tumors.Roche

>> Astellas Pharma is dishing out up to $37 milYL211in upfront and license option fees to Elpiscience Biopharma in a research and lisolid tumorsent for novel bi-specific macrophage engagers, the anti-PD-L1/SIRPα bispecific antibody ES019 and another program, according to a Dec. 28 announcement.

TheAstellas Pharma-based biotech could receive as much as $1.7 billion in future developmeElpiscience Biopharmammercial milestones. Astellas could also opt in for a further two programs.ES019

>> Codexis is offloading exocrine pancreatic insufficiency treatment CDX-7108 to Nestlé Health Science for $45 million total, includAstellas million upfront fee, according to a December 27 release. The deal also includes royalties and could bring an additional $5 million for the biotech if Nestlé decides to opt in on two additional early-stage enzymes in development for the condition.

TheCodexis engineering biexocrine pancreatic insufficiencyritized in CDX-7108 202Nestlé Health Science Nestlé

The decision to hand CDX-7108 over to Nestlé will remove cash burn from development and commercialization costs, according to the latest release.

>> Atreca, also reeliCDX-7108a slate oNestléffs last year, has found a buyer for a collection of antibody-related assets and materials. Immunome has offered to pick up the assets for $12.5 million, including $5.5 million upfront and up to $7 million in clinical milestones, according to a Dec. 26 press release.

TheAtrecaincludes APN-497444, which was Atreca’s lead ADC program in early development for gastrointestinal cancers.Immunome

At the time of theAPN-497444nt layoffs iAtrecamber, Atreca CEO John Orwin said the company gastrointestinal cancersing APN-497444 through preclinical testing, but cash was running very low. Now, he says the company is “encouraged that Immunome also recognizes” the potential of its tumor-targeting antibodies.

Atreca’s shareholders will need to approve the sale,Atrecaa plan of dissolution calling for the liquidation of any remaAPN-497444ts included in the vote, according to the release.Immunome tumor

AtrecaChristmas deals:

AstraZeneca pays $1B to take the wheel of Gracell’s CAR-T ‘fast car’

AstraZenecaould forgive some Big Pharmas fGracelling away from CAR-Ts in the wake of the FDA’s decision to investigate the risk of secondary cancers, AstraZeneca has decided that a cell therapy company would make the perfect Christmas present. Story here

BMS enters radiopharma race with $4.1B acquisition of RayzeBio just 3 months after biotecFDAent publicsecondary cancers AstraZeneca

BMSre’s been no festive respite for Bristol Myers SquiRayzeBio team as the Big Pharma follows up its acquisition of Karuna Therapeutics with the announcement straight after Christmas that it is also buying radiopharmaceuticals-focused RayzeBio for cash. Story here